2021 Annals Manuscript Review #5

Only physicians who have been selected by the editors of the Annals to successfully complete manuscript reviews may register for this activity. Please note: there is a maximum of 15 credits per year.

Reviewers may earn up to 3.0 AMA PRA Category 1 Credit(s)TM each completed review that receives a passing score. Each reviewer can claim credit for up to 5 reviews each calendar year. To complete this activity and earn credit, you will need the manuscript number you reviewed. Please email the editorial office of the Annals if you do not have this information. Credit should be claimed by December 31, 2021 to be counted for 2021. The course will be unavailable after this date.

To begin, click on Annals Manuscript Review #1 and then click Take Course. As usual, a brief course evaluation must be completed for each manuscript prior to claiming credit. For any subsequent reviews, return to this course and click the next Annals Manuscript Review number. Please only claim credit for the articles you have reviewed.

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 3 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Additional information

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

All relevant financial relationships have been mitigated.

  • Gailen D. Marshall, Jr., MD, PhD, No relevant financial relationships to disclose.
  • Mitchell Grayson, MD, Advisory Board, Consulting Fee: DBV Technologies, GlaxoSmithKline.
  • Anne E. Ellis, MD, MSC, Advisory Board, Honorarium: Alk Abello, AstraZenca, Aralez, Bausch Health, LEO Pharma, Merck, Novartis, Pfizer; Speaker, Honorarium: Alk Abello, Aralez, AstraZeneca,Medexus, Mylan: Research Grants: Alk Abello, Aralez, AstraZeneca, Bayer, LLC. Medexus, Novartis, Regeneron; Independent Consultant, Fees: Bayer LLC, Regeneron.
  • Anna Nowak-Wegrzyn, MD, PhD, Advisory Board, Honorarium: Nestle; Novartis, Regeneron; Speaker, Honorarium: Nutricia; Author, Royalty: UpToDate.
  • Donald Y.M. Leung, MD, Advisory Board, Consulting Fee: Boehringer Ingelheim; Consultant, Honorarium: Genentech; Advisory Board, Honorarium: Leo Pharma; Speaker, Honorarium: Pfizer.
  • William D. Johnson, PhD, No relevant relationships to disclose.
  • Larry Borish, MD, Consultant, Consulting Fee: Avrio-Purdue; Advisory Board, Consulting Fee: Bristol Myers Squibb, Genzyme, Sanofi; Clinical Research:, Contracted Research: Regeneron, Money to Institution; Investigator, Grant: Money to Institution: GlaxoSmithKline.
  • Mariana C. Castells, MD, PhD, No relevant relationships to disclose.
  • Matthew Greenhawt, MD, Consultant, Fee: Aquestive; Advisory Board, Honorarium: Allergenis, Allergy Therapeutics, Aquestive, DBV Technologies, Intrommune, Novartis, Nutricia, Pfizer, Prota, Sanofi/Genzyme, US WorldMeds; Speaker, Honorarium: DBV Technologies.
  • Jay A. Lieberman, MD, Author, Research Investigator, Contracted Research, Money to Institution: Aimmune: Advisory Board, Research Investigator, Honorarium, Contracted Research, Money to Institution: DBV Technologies; Advisory Board, Honorarium: Genentech; Research Investigator, Contracted Research, Money to Institution: Regeneron.
  • John J. Oppenheimer, MD, Consultant, Consulting Fee: AstraZeneca; Research, Consulting Fee: GlaxoSmithKline; Adjudication/dsmb, Consulting Fee: Novartis, Abbvie, Regeneron, Sanofi.
  • Jonathan Spergel, MD, PhD. Independent Contractor, Honorarium: Abbott; Consultant, Independent Contractor, Consulting Fee, Contracted Research: DBV Technologies; Advisory Board, Contracted Research, Honorarium: Novartis; Consultant, Independent Contractor, Consulting: Intellectual Property Rights, Regeneron; Independent Contractor, Contracted Research: Sanofi.
Course summary
Available credit: 
  • 3.00 AMA PRA Category 1 Credit™
  • 3.00 Attendance
Course opens: 
Course expires: 

Available Credit

  • 3.00 AMA PRA Category 1 Credit™
  • 3.00 Attendance
Please login or create an account to take this course.